High-Affinity IgE Blockade & Allergic Disease Therapeutics: Market Intelligence, Clinical Progress, and High-Purity Reagents for Asthma, CSU, Food Allergy, and Atopic Dermatitis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IGHE-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Human IGHE Constant Region Recombinant Protein (Cε2–Cε4) & Domain Deletion Mutant Panel High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, HEK293 Expressed (native glycosylation) |
View IGHE Products |
| Gene Delivery | IGHE Promise-ORF / Lentivirus Full-length ORF for stable IgE-expressing cell lines; Native glycosylation pattern |
View IGHE Products |
| Benchmark Ab | Anti-IGHE (Omalizumab Biosimilar Sequence) Recombinant human IgG1κ positive control; Sequence Verified |
View IGHE Products |
| Validator | IGHE siRNA Set (3 unique sequences) For knockdown verification and specificity controls |
View IGHE Products |
| Related Target A | FCER1A (High-Affinity IgE Receptor α-Chain) Critical for FcεRI competition and functional blocking assays; Synergistic pathway |
View FCER1A Products |
| Related Target B | FCER2 / CD23 (Low-Affinity IgE Receptor) Involved in IgE regulation and transport; Epitope safety screening |
View FCER2 Products |
| Related Target C | IL4R (IL-4 Receptor Alpha) Synergistic pathway target for severe asthma and Type 2 inflammation; Used in combined blockade studies |
View IL4R Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Domain-Level Epitope Mapping (Cε3 vs Cε4) | IGHE Domain Deletion Mutant Panel; Sequence verified by Mass Spec; HEK293 expressed for native folding |
| Receptor Cross-Linking Risk (Anaphylaxis) | Purified native-folded IGHE proteins and FCER1A receptors for validating strictly non-anaphylactogenic binding |
| Cross-Species Toxicology (Cyno/Mouse) | Human / Cynomolgus / Mouse IGHE ortholog proteins available with >95% purity; Endotoxin Controlled |
| Glycosylation-Dependent Affinity | HEK293 Expressed (Native Glycosylation) ensures proper structural conformation of IgE Fc domain |
| Epitope Specificity (Free vs. Receptor-Bound IgE) | FCER1A Recombinant Protein for complex formation assays; Theoretical MW verified by Mass Spec |
| High-Concentration Sub-Q Formulation | IGHE Protein aggregation-tested; Suitable for viscosity and stability screening at therapeutic concentrations |
| Lack of Specificity Controls | IGHE siRNA Set included for target validation; Eliminate off-target assay artifacts |
Live IGHE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGHE-targeted therapeutics is intensifying, with major players shifting focus from first-generation IgE blockade (Omalizumab) to next-generation high-affinity antibodies (Ligelizumab paradigm), biosimilars, bispecific molecules, and mIgE-depleting strategies. As Omalizumab biosimilars enter the market, differentiation emphasizes superior affinity (sub-nM Kd), pH-dependent binding for extended half-life, memory B-cell depletion (targeting mIgE), and combination with upstream cytokine pathways (e.g., IL-4Rα, TSLP). The next wave of R&D targets chronic spontaneous urticaria (CSU), severe food allergies, pediatric populations, and chronic rhinosinusitis with nasal polyps (CRSwNP), requiring rigorous preclinical validation using high-purity, native-conformation IGHE antigens and cross-species orthologs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| High-Affinity mAb | Novartis (Ligelizumab), United BioPharma | CSU, Asthma, Food Allergies | Sub-nM SPR Kinetics (need high-purity IGHE antigen for accurate affinity determination) |
| Anti-IgE Biosimilar | Various (Post-Xolair) | Allergic Asthma, CSU | Epitope Mapping vs. Omalizumab (Benchmark Ab required) |
| Bispecific (IgE x IL-5 / IgE x IL-4R) | Sanofi, Regeneron, Emerging Biotech | Eosinophilic Asthma, Atopic Dermatitis | Dual-Affinity Validation (cross-reactive species orthologs and heterodimer assays) |
| mIgE Depleting Ab | Genentech (Quilizumab - Discontinued) | Chronic Allergic Disease | Membrane IgE distinction (need Lentivirus for stable mIgE-expressing cell lines) |
Key Domains and Known Mutations
IGHE (UniProt P01854) contains three immunoglobulin-like (Ig-like) domains: Ig-like 1 (Cε2), Ig-like 2 (Cε3), and Ig-like 3 (Cε4). The Cε3 domain contains the binding interface for the high-affinity FcεRI receptor; antibodies that bind this domain can block IgE-receptor interaction but risk receptor cross-linking if not carefully selected. A key sequence variant is defined in the IMGT allele IGHE*01 (UniProt VAR_044229), which represents the common allele for assay standardization. Domain deletion mutants and allele-specific proteins are critical for epitope binning and patient stratification studies, and TarMart provides these reagents with sequence verification.